SCHEMBL23220337

SCHEMBL23220337

c1ccc(Nc2nnc(CCCc3nnc(Nc4ccccc4)s3)s2)cc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GLS O94925 12/20 0.54
SMN1; SMN2 Q16637 4/20 0.51
NPC1 O15118 4/20 0.51
RAB9A P51151 3/20 0.51
GSK3B P49841 1/20 0.50
ALDH1A1 P00352 3/20 0.49
LMNA P02545 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
MAPT P10636 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TP53 P04637 1/20 0.49
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
KMT2A Q03164 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23220309 0.96 GLS (0.54) GLSSMN1; SMN2NPC1RAB9AGSK3B
SCHEMBL19003798 0.95 GLS (0.55) GLSSMN1; SMN2NPC1RAB9AGSK3B
SCHEMBL23220293 0.93 NPC1 (0.54) GLSSMN1; SMN2NPC1RAB9AGSK3B
SCHEMBL28568225 0.89 RAB9A (0.53) GLSSMN1; SMN2NPC1RAB9AGSK3B
SCHEMBL19003801 0.88 NPC1 (0.50) GLSSMN1; SMN2NPC1RAB9AGSK3B
SCHEMBL23220315 0.88 GLS (0.49) GLSSMN1; SMN2NPC1RAB9AGSK3B
SCHEMBL19003738 0.86 NPC1 (0.49) GLSSMN1; SMN2NPC1RAB9AGSK3B
SCHEMBL23220326 0.86 NPC1 (0.49) GLSSMN1; SMN2NPC1RAB9AGSK3B
SCHEMBL28568230 0.86 RAB9A (0.65) SMN1; SMN2NPC1RAB9AGSK3BALDH1A1
SCHEMBL23220320 0.85 KMT2A (0.57) SMN1; SMN2NPC1RAB9AGSK3BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975048-B2 Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity HANGZHOU JENNIFER BIOTECH CO LTD (CN) 2021-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975048-B2 Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity GPX4, GPX1, SELENOI GLS 54/4885SMN1; SMN2 2905/4885NPC1 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.